Filtered By:
Source: Cell Research
Vaccination: Cancer Vaccines
This page shows you your search results in order of date. This is page number 2.
Order by Relevance | Date
Total 154 results found since Jan 2013.
Rewiring innate and adaptive immunity with TLR9 agonist to treat osteosarcoma
CONCLUSIONS: Overall these data indicate that the TLR9 agonist acts as an in situ anti-tumor vaccine, activating an innate immune response sufficient to suppress local tumor growth while inducing a systemic adaptive immunity with selective expansion of CD8 T cell clones, which are needed for the abscopal effect.PMID:37365634 | PMC:PMC10291774 | DOI:10.1186/s13046-023-02731-z
Source: Cell Research - June 26, 2023 Category: Cytology Authors: Caterina Cascini Chiara Ratti Laura Botti Beatrice Parma Valeria Cancila Adriana Salvaggio Cristina Meazza Claudio Tripodo Mario P Colombo Claudia Chiodoni Source Type: research
Comprehensive landscape of the miRNA-regulated prognostic marker LAYN with immune infiltration and stemness in pan-cancer
CONCLUSION: This study elucidated the functional mechanisms of LAYN from a pan-cancer perspective and provided novel insights into cancer prognosis, metastasis, and immunotherapy. LAYN has the potential to become a new target of mRNA vaccines and molecular therapies in tumors.PMID:37335337 | DOI:10.1007/s00432-023-04986-7
Source: Cell Research - June 19, 2023 Category: Cytology Authors: Wang Jiawen Wang Jinfu Liu Jianyong Zhang Yaoguang Wang Jianye Source Type: research
Development of HPV16 mouse and dog models for more accurate prediction of human vaccine efficacy
CONCLUSIONS: In this study, we have developed two animal models, with a genetic design that is easily transposable to different antigens, to validate the efficacy of candidate vaccines. Our results indicate that, despite being immunogenic, the C216 candidate vaccine did not induce a sufficiently strong immune response to eliminate infected cells. Our results are in line with the failure of the ProCervix vaccine that was observed at the end of the phase II clinical trial, reinforcing the relevance of appropriate animal models.PMID:37308929 | DOI:10.1186/s42826-023-00166-3
Source: Cell Research - June 12, 2023 Category: Cytology Authors: Emmanuelle Totain Lo ïc Lindner Nicolas Martin Yolande Misseri Alexandra Ich é Marie-Christine Birling Tania Sorg Yann Herault Alain Bousquet-Melou Pascale Bouill é Christine Duthoit Guillaume Pavlovic Severine Boullier Source Type: research
Longitudinal data on humoral response and neutralizing antibodies against SARS-CoV-2 Omicron BA.1 and subvariants BA.4/5 and BQ.1.1 after COVID-19 vaccination in cancer patients
CONCLUSION: We present the first data on nAb against BQ.1.1 following the third vaccination in cancer patients. Our results highlight the threat that new emerging SARS-CoV-2 variants pose to cancer patients and support efforts to apply repeated vaccines. Since a considerable number of patients did not display an adequate immune response, continuing to exhibit caution remains reasonable.PMID:37300723 | DOI:10.1007/s00432-023-04961-2
Source: Cell Research - June 10, 2023 Category: Cytology Authors: Oliver Overheu Simon Lendowski Daniel R Quast Daniel K ühn Elena Vidal Blanco Anna-Lena Kraeft Eike Steinmann Eleni Kourti Celine Lugnier Joerg Steinmann Anke Reinacher-Schick Stephanie Pfaender Source Type: research
Extracellular vesicle-based drug delivery in cancer immunotherapy
Drug Deliv Transl Res. 2023 Jun 1:1-17. doi: 10.1007/s13346-023-01370-3. Online ahead of print.ABSTRACTExtracellular vesicles (EVs) are a group of nanoscale membrane-bound organelles including exosomes, microvesicles (MVs), membrane particles, and apoptotic bodies, which are released from almost all eukaryotic cells. Owing to their ingredients, EVs can be employed as biomarkers for human diseases. Interestingly, EVs show favorable features as candidates for targeted drug delivery and thus, they are suggested as ideal drug carriers as well as good vaccines for various human diseases including cancer. Among various drugs loa...
Source: Cell Research - June 1, 2023 Category: Cytology Authors: Sajad Najafi Jamal Majidpoor Keywan Mortezaee Source Type: research
Phase II Trial of Nelipepimut-S Peptide Vaccine in Women with Ductal Carcinoma In Situ
Cancer Prev Res (Phila). 2023 Jun 1;16(6):333-341. doi: 10.1158/1940-6207.CAPR-22-0388.ABSTRACTNeuVax is a vaccine comprised of the HER2-derived MHC class I peptide E75 (nelipepimut-S, NPS) combined with GM-CSF. We completed a randomized trial of preoperative vaccination with NeuVax versus GM-CSF alone in patients with ductal carcinoma in situ (DCIS). The primary objective was to evaluate for NPS-specific cytotoxic T lymphocyte (CTL) responses. Patients with human leukocyte antigen (HLA)-A2-positive DCIS were enrolled and randomized 2:1 to NeuVax versus GM-CSF alone and received two inoculations prior to surgery. The numbe...
Source: Cell Research - June 1, 2023 Category: Cytology Authors: Anne E O'Shea Guy T Clifton Na Qiao Brandy M Heckman-Stoddard Malgorzata Wojtowicz Eileen Dimond Isabelle Bedrosian Diane Weber Judy E Garber Alexander Husband Ricardo Pastorello J Jack Lee Mike Hernandez Diane D Liu Lana A Vornik Powel H Brown Gheath Ala Source Type: research
Immunogenicity of the ChAdOx1 nCoV-19 vaccine in patients with hematologic malignancies
CONCLUSION: Immune responses were impaired in individuals with hematologic malignancies, particularly patients undergoing ongoing therapy and B-cell-depleting therapy. Additional vaccinations should be considered for these patients, and further investigated.PMID:37214149 | PMC:PMC10193112 | DOI:10.7774/cevr.2023.12.2.107
Source: Cell Research - May 22, 2023 Category: Cytology Authors: Chayapa Thookhamme Manassamon Navinpipat Aimwipa Sasakul Pakthipa Pattarakosol Kamoltip Lertchaisataporn Kriangkrai Tawinprai Pannee Praditsuktavorn Source Type: research
Personalized dendritic cell vaccination in cancer therapy: An evidence-based research study
CONCLUSION: Dendritic cell therapies could prove to be a valuable tool in cancer treatment.PMID:37147983 | DOI:10.4103/jcrt.jcrt_522_21
Source: Cell Research - May 6, 2023 Category: Cytology Authors: Eleana Hatzidaki Ioannis Papasotiriou Source Type: research
A Phase I/II trial of HER-2/neu vaccine primed autologous T-cell infusions in patients with treatment refractory HER-2/neu overexpressing breast cancer
CONCLUSIONS: Adoptive transfer of HER2 vaccine primed T-cells was feasible, associated with minimal toxicity, and resulted in an increased overall survival in responding patients.PMID:37093223 | DOI:10.1158/1078-0432.CCR-22-3578
Source: Cell Research - April 24, 2023 Category: Cytology Authors: Mary L Disis Yushe Dang Andrew L Coveler Jennifer S Childs Doreen M Higgins Ying Liu Jing Zhou Sean Mackay Lupe G Salazar Source Type: research
Exosomes: a potential diagnostic and treatment modality in the quest for counteracting cancer
CONCLUSION: In this review, the physiological roles played by exosomes were summarized along with their biogenesis process. Different isolation techniques of exosomes including centrifugation-based, size-based, and polymer precipitation-based techniques have also been described in detail with a special focus on cancer therapeutic applications. The review also shed light on techniques of incubation of drugs with exosomes and their characterization methods covering the most advanced techniques. Myriad applications of exosomes in cancer as diagnostic biomarkers, drug delivery carriers, and chemoresistance-related issues have ...
Source: Cell Research - April 11, 2023 Category: Cytology Authors: Gayatri Patel Tejas Girish Agnihotri Manoj Gitte Tanuja Shinde Shyam Sudhakar Gomte Roshan Goswami Aakanchha Jain Source Type: research
Tumour-derived extracellular vesicle based vaccines for melanoma treatment
Drug Deliv Transl Res. 2023 Apr 6. doi: 10.1007/s13346-023-01328-5. Online ahead of print.ABSTRACTThe interest of extracellular vesicles (EVs) in cancer immunotherapy is increasing every day. EVs are lipid bilayer vesicles released by most cells, which contain the molecular signature of their parent cell. Melanoma-derived EVs present antigens specific to this aggressive type of cancer, but they also exert immunomodulatory and pro-metastatic activity. Until now, most reviews focus on the immunoevasive characteristics of tumour-derived EVs, but do not help to overcome the issues related to them. In this review, we describe i...
Source: Cell Research - April 6, 2023 Category: Cytology Authors: Lorena Gonzalez-Melero Rosa Maria Hernandez Edorta Santos-Vizcaino Manoli Igartua Source Type: research
Vaccination and microbiota manipulation approaches for colon cancer prevention in rodent models
Cancer Prev Res (Phila). 2023 Apr 4:CAPR-23-0015. doi: 10.1158/1940-6207.CAPR-23-0015. Online ahead of print.ABSTRACTColorectal cancer (CRC) represents the third most common cancer type worldwide and is a leading cause of cancer-related mortality in the US and Western countries. Rodent models have been invaluable to study the etiology of CRC and to test novel chemoprevention avenues. In the past, the laboratory mouse has become one of the best preclinical models for these studies due to the availability of genetic information for commonly used mouse strains with well-established and precise gene targeting and transgenic te...
Source: Cell Research - April 3, 2023 Category: Cytology Authors: Elena Tosti Nityanand Srivastava Winfried Edelmann Source Type: research
The immunopeptidome from a genomic perspective: Establishing the non-canonical landscape of MHC class I-associated peptides
Cancer Immunol Res. 2023 Mar 24:CIR-22-0621. doi: 10.1158/2326-6066.CIR-22-0621. Online ahead of print.ABSTRACTTumor antigens can emerge through multiple mechanisms, including translation of non-coding genomic regions. This non-canonical category of antigens has recently gained attention; however, our understanding of how they recur within and between cancer types is still in its infancy. Therefore, we developed a proteogenomic pipeline based on deep learning de novo mass spectrometry to enable the discovery of non-canonical MHC-associated peptides (ncMAPs) from non-coding regions. Considering that the emergence of tumor a...
Source: Cell Research - March 24, 2023 Category: Cytology Authors: Georges Bedran Hans-Christof Gasser Kenneth Weke Tongjie Wang Dominika Bedran Alexander Laird Christophe Battail Fabio Massimo Zanzotto Catia Pesquita H åkan Axelson Ajitha Rajan David J Harrison Aleksander Palkowski Maciej Pawlik Maciej Parys J Robert O Source Type: research
Antitumor effect of neoantigen-reactive T cells combined with PD1 inhibitor therapy in mouse lung cancer
CONCLUSION: The adoptive transfer of NRT cells in association with anti-PD1 therapy can exert an antitumor effect on lung cancer, and is a feasible, effective, and novel immunotherapy regimen for treating solid tumors.PMID:36933035 | DOI:10.1007/s00432-023-04683-5
Source: Cell Research - March 18, 2023 Category: Cytology Authors: Huan Qin Haiyan Hu Ximing Liao Pei Zhao Wenjuan He Xiaoping Su Jiaxing Sun Qiang Li Source Type: research
